YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Adagene Inc. Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established Data rep…
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
Adagene Inc. (NASDAQ:ADAG) is one of the 10 Unstoppable Stocks That Could Double Your Money. Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration w…
In late March and early April 2026, Incyte reported positive 54-week Phase 3 data for its JAK1 inhibitor povorcitinib in hidradenitis suppurativa and Adagene announced entering a clinical collaboration with Incyte to test a combination imm…
Adagene Inc. Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patientswith and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Coll…
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patientswith and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Collaboration pro…
Dose-Dependent Efficacy Results: As of the latest data cut, muzastotugachieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/39) in the combined 10…
* Adagene ADR press release [https://seekingalpha.com/pr/20460114-adagene-reports-full-year-2025-financial-results-and-provides-corporate-update] (ADAG [https://seekingalpha.com/symbol/ADAG]): FY Non-GAAP EPS of -$0.24 beats by $0.41. * Re…
In 2025, muzastotugshowed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months 4…
SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug…
Shares of Moderna, Inc. MRNA rose 5.3% on Friday, Feb. 13, as investors showed renewed interest in large-cap biotech names. The gain stood out against a choppy broader market, suggesting traders were selectively rotating into healthcare st…
Adagene Inc. ADAG announced that the FDA has granted Fast Track designation to its lead clinical-stage immuno-oncology candidate, muzastotug (ADG126). The designation was granted to muzastotug in combination with Merck’s anti-PD-1 therapy…
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index falling 1.6% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Adagene Inc. Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADA…
SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) and Third Arc Bio, Inc. (“Third Arc Bio”), today announced a licensing agreement under which Third Arc Bio will ut…
As the U.S. stock market shows signs of strength with major indices on track for weekly and monthly gains, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, though often overlooked due…
Adagene Inc. Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRU…
Company Logo The CD47-targeted therapy market is poised for growth due to its potential in treating resistant cancers. With over 80 drugs in trials, innovations like bispecific antibodies, combination therapies, and personalized treatment…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adagene Inc. Sponsored ADR (ADAG) is a stock that can certainly grab the attention of many investors, but do its recent ret…
On September 16, 2025, Adagene Inc. announced an amendment to its 2021 collaboration and license agreement with Exelixis, allowing Exelixis to use Adagene's SAFEbody technology platform to generate a masked monoclonal antibody for developm…
Adagene Inc. SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adagene Inc. Sponsored ADR (ADAG) one of those stocks right now? Let's take a closer look at the sto…
Adagene Inc. SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced th…
SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 wil…
SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as…
SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s C…
As the U.S. stock market experiences a downturn with the S&P 500 declining for a fourth consecutive day, investors are keenly focused on upcoming signals from Federal Reserve Chair Jerome Powell regarding interest rates. In such fluctuatin…
Adagene Inc. Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. Company ex…
Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. Company expects to begi…
Adagene Inc. - Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAN DI…
- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAN DIEGO and SUZHO…
Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transfor…
Health care stocks were leaning lower premarket Tuesday with the iShares Biotechnology ETF (IBB) and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Collaboration concept in word tag cloud] rafal_olechowski * Adagene (NASDAQ:ADAG [https://seekingalpha.com/symbol/ADAG]) ADRs added ~16% in the premarket on Tuesday after Sanofi (NASDAQ:SNY [https://seekingalpha.com/symbol/SNY]) expanded…
- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - Company expects proceeds to extend cash runway into 2027 SAN DIEGO and SUZHOU, China, July 01, 2025 (GLOBE NEWSWIRE) -…
Adagene Inc. - Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - Company expects proceeds to extend cash runway into 2027 SAN DIEGO and SUZHOU, China, July 01, 2025 (GLOB…